USFDA completes inspection of Lupin’s Nagpur facility

13 Jan 2020 Evaluate

United States Food and Drug Administration (USFDA) has completed a Prior Approval Inspection (PAI) at Lupin’s Nagpur oral solid dosage manufacturing facility. The inspection was carried out between January 6, 2020 and January 10, 2020. The inspection closed with two 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×